Glenmark Pharmaceuticals Ltd. (GLENMARK): Glenmark Pharmaceuticals Share Price Rises 2.23% to Rs 2,433.15
- September 21, 2026
- Posted by: Harsh Piplani
- Category: News
Glenmark Pharmaceuticals Share Price rose to Rs 2,433.15 today, up 2.23% from the previous close of Rs 2,380, while the company’s market capitalisation stood at Rs 67,169.47 crore. The stock’s move keeps Glenmark Pharmaceuticals Ltd. in focus among healthcare names on the NSE and BSE, although the supplied data confirms the price event and does not establish a company-specific catalyst. In this Glenmark Pharmaceuticals Share Price update, Univest tracks the move alongside the day’s narrow trading band, valuation profile and sector comparison. For readers following Glenmark Pharmaceuticals Stock News, the key question is not only what changed today but also how the current price fits against the company’s fundamentals, healthcare peers and broader Industry analysis. That is the context investors can monitor next on Univest.
Glenmark Pharmaceuticals Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 2,433.15 |
| Previous Close | Rs 2,380 |
| Today's Move | Rs 53.15 (+2.23%) |
| Open | Rs 2,426.85 |
| High | Rs 2,433.15 |
| Low | Rs 2,426.8 |
| Turnover | Rs 0.03 crore |
| Market Capitalisation | Rs 67,169.47 crore |
| Market Cap Category | Large Cap |
Glenmark Pharmaceuticals Ltd. (GLENMARK) rose to Rs 2,433.15 from the previous close of Rs 2,380, a move of Rs 53.15 or 2.23%. The stock opened at Rs 2,426.85, reached a high of Rs 2,433.15, recorded a low of Rs 2,426.8.
The Glenmark Pharmaceuticals Share Price Today move was a same-day gain of Rs 53.15, or 2.23%, to Rs 2,433.15. The stock opened at Rs 2,426.85, touched a low of Rs 2,426.80 and a high of Rs 2,433.15, so the session stayed within a narrow range. Turnover stood at Rs 0.03 crore. With the current price matching the day high and staying above the previous close of Rs 2,380, the price action confirms a positive session without supplying any additional cause. For Glenmark Pharmaceuticals Share Price Today watchers, the verified data shows a clean upward finish and a short intraday band.
Glenmark Pharmaceuticals Ltd. (GLENMARK) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 67,169.47 crore |
| P/E Ratio | 37.36x |
| P/B Ratio | 6.13x |
| ROE | 14.1% |
| ROCE | 20.35% |
| EPS | Rs 63.7 |
| Book Value Per Share | Rs 388.43 |
| Dividend Yield | 0.11% |
Glenmark Pharmaceuticals Ltd. (GLENMARK) fundamental metrics show P/E 37.36x, P/B 6.13x, ROE 14.1%, ROCE 20.35%. These figures provide context only and are not a buy or sell signal.
Glenmark Pharmaceuticals Ltd. has a market capitalisation of Rs 67169.47 crore and falls in the Large Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 37.36x, P/B at 6.13x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 14.1% and ROCE of 20.35%, helping investors compare shareholder returns and capital efficiency. Additional supplied metrics include EPS of Rs 63.7, book value per share of Rs 388.43, dividend yield of 0.11%, adding context to earnings, balance-sheet value and historical payout. Against the supplied same industry benchmark, these figures can be compared with benchmark median P/E of 32.87x, median ROE of 11.7%, median ROCE of 13.46%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 37.36x |
| Benchmark Median P/E | 32.87x |
| Benchmark Average P/E | 48.77x |
| Benchmark P/E Range | 3.4x to 683.5x |
| Company P/B Ratio | 6.13x |
| Benchmark Median P/B | 3.08x |
| Company ROE | 14.1% |
| Benchmark Median ROE | 11.7% |
| Company ROCE | 20.35% |
| Benchmark Median ROCE | 13.46% |
| Company Market Capitalisation | Rs 67,169.47 crore |
| Benchmark Median Market Cap | Rs 701.78 crore |
Glenmark Pharmaceuticals Ltd. (GLENMARK) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.
Glenmark Pharmaceuticals Ltd. (GLENMARK) has a P/E ratio of 37.36x, which is above the benchmark median of 32.87x, a difference of +13.66%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Glenmark Pharmaceuticals Ltd. (GLENMARK) has a ROE of 14.1%, which is above the benchmark median of 11.7%, a difference of +20.51%. Glenmark Pharmaceuticals Ltd. (GLENMARK) has a ROCE of 20.35%, which is above the benchmark median of 13.46%, a difference of +51.19%.
Track stocks leading today through the Univest top gainers screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | SUNPHARMA | 4,40,397.93 | 36.41 | 5.09 | 14.85 | 19.11 |
| Divi's Laboratories Ltd. | DIVISLAB | 2,48,664.42 | 85.01 | 14.08 | 16.19 | 21.51 |
| Torrent Pharmaceuticals Ltd. | TORNTPHARM | 1,82,738.23 | 83.79 | 20.36 | 26.76 | 19.27 |
| Zydus Lifesciences Ltd. | ZYDUSLIFE | 1,15,012.19 | 25.48 | 4.27 | 19.69 | 21.39 |
| Cipla Ltd. | CIPLA | 1,10,793.75 | 32.87 | 3.15 | 11.83 | 16 |
Glenmark Pharmaceuticals Ltd. (GLENMARK) has a P/E ratio of 37.36x compared with the displayed peer median of 36.41x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 14.1% compares with a peer median of 16.19% across the companies shown in the table. ROCE stood at 20.35% versus the displayed peer median of 19.27%, providing a capital-efficiency comparison. Glenmark Pharmaceuticals Ltd. (GLENMARK) has a market capitalisation of Rs 67,169.47 crore. Among the 5 peers shown, 5 have a larger market capitalisation.
Why Investors Are Watching Glenmark Pharmaceuticals
- The Glenmark Pharmaceuticals Share Price rose 2.23% today to Rs 2,433.15.
- The stock ended the session at the day high of Rs 2,433.15 after opening at Rs 2,426.85.
- Market capitalisation stood at Rs 67,169.47 crore, giving Glenmark Pharmaceuticals Share Price a defined size context.
- P/E at 37.36 and P/B at 6.13 place the stock above the industry median on valuation metrics.
- ROE of 14.1%, ROCE of 20.35%, EPS of Rs 63.7 and book value of Rs 388.43 provide financial context for Glenmark Pharmaceuticals Share Price.
About Glenmark Pharmaceuticals
Glenmark Pharmaceuticals Ltd. operates in the Healthcare sector and the Pharmaceuticals & Drugs industry. The company is known for pharmaceutical products and related healthcare businesses, and its stock is listed on the NSE and BSE. Based on the supplied data, investors looking at Glenmark Pharmaceuticals Company News should focus on the company’s earnings quality, valuation and market position rather than any assumed short-term story. The company’s financial profile includes revenue-linked market interest, an EPS of Rs 63.7, book value of Rs 388.43 and dividend yield of 0.11%, which together offer a compact picture of the business’s reported fundamentals. Glenmark Pharmaceuticals Stock Performance is therefore best understood through its operating profile, profitability metrics and peer comparisons in the healthcare universe. Univest uses this section to place the share price move into a company-level context that is factual and easy to compare with the broader pharmaceutical space.
Track Glenmark Pharmaceuticals Share Price on Univest
Use Glenmark Pharmaceuticals Ltd. (GLENMARK) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top-gainers lists and related market analysis.
You can track Glenmark Pharmaceuticals Share Price on Univest for live share price updates, market capitalisation, financial ratios, shareholding pattern, 52-week levels and company insights. Univest also helps readers follow Glenmark Pharmaceuticals Share Price Today alongside sector context, peer comparison and company fundamentals in one place. For those monitoring Glenmark Pharmaceuticals Latest News, this makes it easier to review Glenmark Pharmaceuticals Share Price Rise, Glenmark Pharmaceuticals Stock News and Glenmark Pharmaceuticals Fundamental Analysis together. The goal is to keep the research view factual, current and simple to follow.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Why did Glenmark Pharmaceuticals Share Price rise today?
Ans. The supplied data confirms that Glenmark Pharmaceuticals Share Price rose 2.23% today to Rs 2,433.15, but it does not establish a company-specific catalyst. The session data instead shows the exact price move, close and intraday range.
What is Glenmark Pharmaceuticals Share Price Today?
Ans. Glenmark Pharmaceuticals Share Price Today is Rs 2,433.15. It was up Rs 53.15, or 2.23%, from the previous close of Rs 2,380, and the stock finished at its day high.
What is Glenmark Pharmaceuticals market capitalisation?
Ans. Glenmark Pharmaceuticals has a market capitalisation of Rs 67,169.47 crore. That places the company well above the same-industry median market cap in the supplied healthcare benchmark and gives scale context to the share price move.
How does Glenmark Pharmaceuticals Share Price compare with sector valuations?
Ans. Glenmark Pharmaceuticals Share Price is supported by a P/E of 37.36 and P/B of 6.13. Both sit above the same-industry median levels, while ROE and ROCE also stand above the benchmark medians.
Is Glenmark Pharmaceuticals profitable based on the supplied data?
Ans. The company’s ROE is 14.1% and ROCE is 20.35%, both above the industry medians. EPS is Rs 63.7, while book value is Rs 388.43 per share, offering a clearer earnings and net-worth snapshot.
How does Glenmark Pharmaceuticals compare with peers?
Ans. Glenmark Pharmaceuticals Share Price sits alongside peers such as Sun Pharmaceutical, Cipla and Zydus Lifesciences. Its P/E is close to Sun Pharmaceutical’s, above Zydus and Cipla, and below several higher-valued pharma names.
Where can I track Glenmark Pharmaceuticals Share Price Live?
Ans. Glenmark Pharmaceuticals Share Price Live can be tracked on Univest, where users can review the latest share price, market cap, valuation ratios, peer data and company-level context in one place.
